Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism
Introduction: Dipeptidyl peptidase-4 (DPP4) has been shown to be a functional receptor for MERS-CoV. An interaction between the viral spike protein and DPP4 is thought to facilitate viral entry. We aimed to find out whether sitagliptin, a member of DPP4 inhibitors, would have beneficial effects in COVID-19 patients. Materials and Methods: In this single center retrospective study, we evaluated 58 patients of whom 16 were on sitagliptin treatment. Molecular docking studies were performed to identify possible interactions between ACE2 and sitagliptin. Results: Sitagliptin use shortened the time to clinical recovery about 3.5 and fastened viral clearance more than 5 days. Resolution of all symptoms was achieved on a mean±standard error (SE) of 2.50 ± 0.40 days in sitagliptin (+) group and 5.69 ± 0.61 days in sitagliptin (-) group (Log-rank test, p< 0.001). PCR tests for SARS-CoV-2 resulted negative in mean ± SE of 7.50 ± 0.98 days in sitagliptin (+) and 13.17 ± 1.07 days in sitagliptin (-) group (Log-rank test, p= 0.003). Compared to day 0, CRP, ferritin and D-dimer levels on days three, five, and seven were significantly lower whereas lymphocyte count was higher in sitagliptin (+) group. Conclusion: Our results suggest that sitagliptin seems to have a potential to be considered for the treatment of COVID-19..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Flora Infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi - 27(2022), 2, Seite 324-334 |
| Sprache: |
Englisch ; Türkisch |
|---|
| Beteiligte Personen: |
Güle ÇINAR [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Ace2 |
|---|
| doi: |
10.5578/flora.20229816 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ016676181 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ016676181 | ||
| 003 | DE-627 | ||
| 005 | 20230310183552.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5578/flora.20229816 |2 doi | |
| 035 | |a (DE-627)DOAJ016676181 | ||
| 035 | |a (DE-599)DOAJ27c18c6a6b5948dfa75cd3bb84f323fa | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a tur | ||
| 050 | 0 | |a RC109-216 | |
| 050 | 0 | |a QR1-502 | |
| 100 | 0 | |a Güle ÇINAR |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Introduction: Dipeptidyl peptidase-4 (DPP4) has been shown to be a functional receptor for MERS-CoV. An interaction between the viral spike protein and DPP4 is thought to facilitate viral entry. We aimed to find out whether sitagliptin, a member of DPP4 inhibitors, would have beneficial effects in COVID-19 patients. Materials and Methods: In this single center retrospective study, we evaluated 58 patients of whom 16 were on sitagliptin treatment. Molecular docking studies were performed to identify possible interactions between ACE2 and sitagliptin. Results: Sitagliptin use shortened the time to clinical recovery about 3.5 and fastened viral clearance more than 5 days. Resolution of all symptoms was achieved on a mean±standard error (SE) of 2.50 ± 0.40 days in sitagliptin (+) group and 5.69 ± 0.61 days in sitagliptin (-) group (Log-rank test, p< 0.001). PCR tests for SARS-CoV-2 resulted negative in mean ± SE of 7.50 ± 0.98 days in sitagliptin (+) and 13.17 ± 1.07 days in sitagliptin (-) group (Log-rank test, p= 0.003). Compared to day 0, CRP, ferritin and D-dimer levels on days three, five, and seven were significantly lower whereas lymphocyte count was higher in sitagliptin (+) group. Conclusion: Our results suggest that sitagliptin seems to have a potential to be considered for the treatment of COVID-19. | ||
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a dpp4 inhibitors | |
| 650 | 4 | |a ace2 | |
| 650 | 4 | |a sitagliptin | |
| 650 | 4 | |a sars-cov-2 | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 653 | 0 | |a Microbiology | |
| 700 | 0 | |a Satı COŞGUN YAZGAN |e verfasserin |4 aut | |
| 700 | 0 | |a Atilla Halil ELHAN |e verfasserin |4 aut | |
| 700 | 0 | |a İrem AKDEMİR KALKAN |e verfasserin |4 aut | |
| 700 | 0 | |a Ezgi GÜLTEN |e verfasserin |4 aut | |
| 700 | 0 | |a Mehmet Altay ÜNAL |e verfasserin |4 aut | |
| 700 | 0 | |a Özgür DEMİR |e verfasserin |4 aut | |
| 700 | 0 | |a Kemal Osman MEMİKOĞLU |e verfasserin |4 aut | |
| 700 | 0 | |a Mehmet Serhat BİRENGEL |e verfasserin |4 aut | |
| 700 | 0 | |a Zeynep Ceren KARAHAN |e verfasserin |4 aut | |
| 700 | 0 | |a Hasan NAZIR |e verfasserin |4 aut | |
| 700 | 0 | |a Ebru EVREN |e verfasserin |4 aut | |
| 700 | 0 | |a Alpay AZAP |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Flora Infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi |d Bilimsel Tip Yayinevi, 2018 |g 27(2022), 2, Seite 324-334 |w (DE-627)DOAJ000080411 |x 1300932X |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2022 |g number:2 |g pages:324-334 |
| 856 | 4 | 0 | |u https://doi.org/10.5578/flora.20229816 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/27c18c6a6b5948dfa75cd3bb84f323fa |z kostenfrei |
| 856 | 4 | 0 | |u http://floradergisi.org/managete/fu_folder/2022-02/324-334%20Gule%20Cinar.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1300-932X |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1308-5115 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2022 |e 2 |h 324-334 | ||